Key statistics
On Friday, Ionis Pharmaceuticals Inc (ISI:BRN) closed at 65.38, 0.00% below its 52-week high of 65.38, set on Dec 05, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 65.38 |
|---|---|
| High | 65.38 |
| Low | 65.38 |
| Bid | 65.46 |
| Offer | 65.64 |
| Previous close | 65.38 |
| Average volume | -- |
|---|---|
| Shares outstanding | 161.97m |
| Free float | 160.96m |
| P/E (TTM) | -- |
| Market cap | 13.73bn USD |
| EPS (TTM) | -1.71 USD |
Data delayed at least 15 minutes, as of Dec 05 2025.
More ▼
Press releases
- DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
- Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
- Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
- Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
- Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
- Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
- DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
- Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
More ▼
